Expectorant syrup with cherry flavour

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

guaifenesin, chlorpheniramine (chlorpheniramine maleate), phenylpropanolamine (phenylpropanolamine hydrochloride)

Available from:

Arpimed LLC

ATC code:

առկա չէ

INN (International Name):

guaifenesin, chlorpheniramine (chlorpheniramine maleate), phenylpropanolamine (phenylpropanolamine hydrochloride)

Dosage:

100mg/5ml+ 2mg/5ml+ 5mg/5ml

Pharmaceutical form:

syrup with cherry flavour

Units in package:

15ml glass bottle-dropper, 60ml glass bottle, 100ml glass bottle

Prescription type:

OTC

Authorization status:

Registered

Authorization date:

2022-03-23

Summary of Product characteristics

SUMMARY PRODUCT CHARACTERISTIC (SPC)
EXPECTORANT
SYRUP
1.1
TRADE NAME
-
Expectorant syrup
1.2 INTERNATIONAL NON-PROPERTY NAME
– Guaifenesin, Chlorpheniramine maleate,
Phenylpropanolamine hydrochloride
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
This
product
contains
100mg
guaifenesin,
2mg
chlorpheniramine
maleate,
5mg
phenylpropanolamine hydrochloride in each 5ml.
_For a full list of excipients, see section 6.1. _
3.
PHARMACEUTICAL FORM
A clear, reddish colored, cherry flavored syrup.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
The clinical uses of Expectorant are treatment of cough, nasal
congestion and cold symptoms. 4.2 POSOLOGY AND ADMINISTRATION
Adults and adolescents of 12 years and above:
The propose therapeutic dose in adults and adolescents is 5 ml of
syrup every 6-8 hours. Do not
take more than 4 doses a day.
Pediatric population between 6-12 years:
The usual therapeutic dose in pediatric between 6-12 years old is
2.5-5 ml every 6-8 hours.
Do not take more than 4 doses a day.
Method of Administration:
For oral use.
4.3 CONTRAINDICATIONS
Hypersensitivity to active substances or to any of the excipients
listed in section 6.1.
Unless your doctor approves, do not use these products if you have:

Heart and circulatory diseases, high blood pressure, insufficient
blood flow in the coronary
arteries as well as other insufficient blood flow including disorders
of the cerebral blood
flow with a tendency to dizziness.

Bronchial asthma, chronic obstructive pulmonary disease (chronic
bronchitis, emphysema),
pneumonia, respiratory depression, respiratory failure.

Severe liver dysfunction (Child-Pugh > 9), severe kidney dysfunction,
pheochromocytoma.

Prostate adenoma with residual urine or other bladder emptying
disorders

Patients with stroke,

Use of MAOIs

Thyroid disease,

Diabetes,

Intolerance with some sugar and fructose,

Increased intraocular pressure (glaucoma),

Epilepsy (children and high-risk groups such as patients with liver
disease or epilepsy),

Pregnan